Top-Rated StocksTop-Rated Cytokinetics Stock Price, News & Analysis (NASDAQ:CYTK) $32.56 -1.33 (-3.92%) (As of 12/5/2023 ET) Add Compare Share Share Today's Range$32.54▼$33.9350-Day Range$26.88▼$36.3252-Week Range$25.98▼$47.49Volume1.22 million shsAverage Volume1.05 million shsMarket Capitalization$3.19 billionP/E RatioN/ADividend YieldN/APrice Target$59.87 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Cytokinetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.93 Rating ScoreUpside/Downside83.9% Upside$59.87 Price TargetShort InterestBearish14.64% of Float Sold ShortDividend StrengthN/ASustainability-0.64Upright™ Environmental ScoreNews Sentiment-0.32Based on 3 Articles This WeekInsider TradingSelling Shares$2.33 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.74) to ($4.32) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.26 out of 5 starsMedical Sector288th out of 948 stocksPharmaceutical Preparations Industry114th out of 421 stocks 4.5 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 14 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $59.87, Cytokinetics has a forecasted upside of 83.9% from its current price of $32.56.Amount of Analyst CoverageCytokinetics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 1.0 Short Interest Percentage of Shares Shorted14.64% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 10.1, which indicates bearish sentiment.Change versus previous monthShort interest in Cytokinetics has recently decreased by 3.11%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 73.99% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.64. Previous Next 1.5 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of -0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cytokinetics this week, compared to 4 articles on an average week.Search InterestOnly 6 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows12 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is an increase of 1,100% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,332,125.00 in company stock.Percentage Held by InsidersOnly 3.80% of the stock of Cytokinetics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.74) to ($4.32) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Cytokinetics Stock (NASDAQ:CYTK)Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesDecember 5, 2023 | markets.businessinsider.comPositive Prescription Trends and Market Dynamics Reinforce Buy Rating for CytokineticsDecember 4, 2023 | markets.businessinsider.comBuy Rating on Cytokinetics: Upcoming Catalysts and Long-Term Commercial ProspectsDecember 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 29, 2023 | finance.yahoo.comCytokinetics Announces Five Presentations at the 34th International Symposium on ALS/MNDNovember 29, 2023 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) Receives Average Recommendation of "Moderate Buy" from AnalystsNovember 24, 2023 | money.usnews.comCytokinetics IncNovember 10, 2023 | markets.businessinsider.comAnticipated SEQUOIA-HCM Study Results Influence Salim Syed’s Buy Rating for CytokineticsNovember 10, 2023 | msn.comGoldman Sachs Initiates Coverage of Cytokinetics (CYTK) with Buy RecommendationDecember 6, 2023 | Financial Alphas (Ad)Countries Are Investing Heavily Into Securing Energy IndependenceThere's a worldwide "arms race" for countries to secure lithium - the critical metal essential to powering the world's green energy transition. While the U.S. is now investing heavily into lithium production, the North American supply chain has fallen far behind. One company is on a mission to change that and make a previously remote area the next great lithium mining hub.November 9, 2023 | markets.businessinsider.comPaul Choi’s Buy Rating on Cytokinetics: Evaluating the Potential and Value of Aficamten and its Market ImpactNovember 9, 2023 | markets.businessinsider.comExpert Ratings for CytokineticsNovember 8, 2023 | msn.comB. Riley Securities Initiates Coverage of Cytokinetics (CYTK) with Buy RecommendationNovember 6, 2023 | msn.comMerck highlights list of healthcare stocks among Mizuho's top picksNovember 3, 2023 | finance.yahoo.comCytokinetics Inc (CYTK) Reports Q3 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comCytokinetics Reports Third Quarter 2023 Financial ResultsNovember 2, 2023 | finance.yahoo.comWall Street Analysts Believe Cytokinetics (CYTK) Could Rally 75.5%: Here's is How to TradeNovember 2, 2023 | markets.businessinsider.comBuy Rating for Cytokinetics: Acquisition Potential and Strong Financial PositionNovember 1, 2023 | za.investing.comPotential Cytokinetics acquirer might wait until pivotal data - TruistOctober 31, 2023 | markets.businessinsider.comAnalysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Axsome Therapeutics (AXSM)October 31, 2023 | reuters.comCytokinetics exploring options after receiving takeover interest - Bloomberg NewsOctober 31, 2023 | msn.comCytokinetics surges amid report of takeover interestOctober 30, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: G1 Therapeutics (GTHX), Coherus Biosciences (CHRS) and Cytokinetics (CYTK)October 27, 2023 | msn.comCytokinetics speculated to be a takeover targetOctober 23, 2023 | finance.yahoo.comCytokinetics to Announce Third Quarter Results on November 2, 2023October 20, 2023 | msn.comHC Wainwright & Co. Maintains Cytokinetics (CYTK) Buy RecommendationOctober 20, 2023 | markets.businessinsider.comHC Wainwright & Co. Maintains Buy Rating for Cytokinetics: Here's What You Need To KnowOctober 20, 2023 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Cytokinetics (CYTK), Medtronic (MDT) and Option Care Health (OPCH)See More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/02/2023Today12/06/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/06/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees409Year Founded1997Price Target and Rating Average Stock Price Target$59.87 High Stock Price Target$80.00 Low Stock Price Target$42.00 Potential Upside/Downside+83.9%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($5.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-388,950,000.00 Net Margins-6,736.12% Pretax Margin-6,739.96% Return on EquityN/A Return on Assets-61.48% Debt Debt-to-Equity RatioN/A Current Ratio7.22 Quick Ratio7.22 Sales & Book Value Annual Sales$7.82 million Price / Sales408.53 Cash FlowN/A Price / Cash FlowN/A Book Value($1.14) per share Price / Book-28.56Miscellaneous Outstanding Shares98,054,000Free Float94,328,000Market Cap$3.19 billion OptionableOptionable Beta0.57 Social Links 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 59)CEO, President & Director Comp: $1.14MMr. Ching W. Jaw (Age 60)Senior VP & CFO Comp: $698.49kMr. Robert C. Wong (Age 55)VP & Chief Accounting Officer Comp: $463.75kDr. Fady Ibraham Malik FACC (Age 59)M.D., Ph.D., Executive Vice President of Research & Development Comp: $776.99kMr. Andrew M. Callos (Age 67)Executive VP & Chief Commercial Officer Comp: $745.4kDr. James A. Spudich Ph.D. (Age 81)Co-Founder & Member of Scientific Advisory Board Comp: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Steven M. Cook (Age 64)Senior Vice President of Supply Chain Operations & Technical Operations Ms. Diane WeiserSenior Vice President of Corporate Communications & Investor RelationsMs. Kari K. Loeser J.D.VP & Chief Compliance OfficerMore ExecutivesKey CompetitorsAxsome TherapeuticsNASDAQ:AXSMAmicus TherapeuticsNASDAQ:FOLDHUTCHMEDNASDAQ:HCMPrestige Consumer HealthcareNYSE:PBHMoonLake ImmunotherapeuticsNASDAQ:MLTXView All CompetitorsInsiders & InstitutionsWellington Management Group LLPSold 284,443 shares on 12/1/2023Ownership: 8.145%American Century Companies Inc.Sold 499,060 shares on 11/30/2023Ownership: 2.270%Neo Ivy Capital ManagementBought 15,944 shares on 11/30/2023Ownership: 0.016%Deutsche Bank AGBought 5,658 shares on 11/24/2023Ownership: 0.211%Public Sector Pension Investment BoardSold 51,112 shares on 11/22/2023Ownership: 0.121%View All Insider TransactionsView All Institutional Transactions CYTK Stock Analysis - Frequently Asked Questions Should I buy or sell Cytokinetics stock right now? 15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 1 hold rating and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks. What is Cytokinetics' stock price target for 2024? 15 equities research analysts have issued 1-year price objectives for Cytokinetics' shares. Their CYTK share price targets range from $42.00 to $80.00. On average, they predict the company's stock price to reach $59.87 in the next twelve months. This suggests a possible upside of 83.9% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts. How have CYTK shares performed in 2023? Cytokinetics' stock was trading at $45.82 at the beginning of the year. Since then, CYTK shares have decreased by 28.9% and is now trading at $32.56. View the best growth stocks for 2023 here. When is Cytokinetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 6th 2024. View our CYTK earnings forecast. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) announced its earnings results on Thursday, November, 2nd. The biopharmaceutical company reported ($1.35) earnings per share for the quarter, missing analysts' consensus estimates of ($0.72) by $0.63. The biopharmaceutical company earned $0.38 million during the quarter, compared to the consensus estimate of $24.71 million. What ETFs hold Cytokinetics' stock? ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Invesco S&P SmallCap Health Care ETF (PSCH), American Century Mid Cap Growth Impact (MID), BNY Mellon Innovators ETF (BKIV), Fidelity Disruptive Medicine ETF (FMED), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap 600 Pure Growth ETF (RZG), Invesco S&P SmallCap Momentum ETF (XSMO) and Principal Healthcare Innovators ETF (BTEC). What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). Who are Cytokinetics' major shareholders? Cytokinetics' stock is owned by many different institutional and retail investors. Top institutional shareholders include FMR LLC (12.23%), Wellington Management Group LLP (8.15%), American Century Companies Inc. (2.27%), Invesco Ltd. (1.21%), Northern Trust Corp (1.09%) and Charles Schwab Investment Management Inc. (0.77%). Insiders that own company stock include B Lynne Parshall, Bvf Partners L P/Il, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Sandford D Smith, Santo J Costa and Wendall Wierenga. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:CYTK) was last updated on 12/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.